An interview with Peter DiBattiste, M.D., Co-Founder and CEO of Prolocor was published in 360Dx. In the interview by Kelsy Ketchum, Dr DiBattiste reviewed the importance of the results of the 800-patient multicenter study that were published in October 2024 in the Journal of the American College of Cardiology, which validated the use of the biomarker FcγRIIa (pFCG) to determine a patient's risk of experiencing a cardiovascular event, such as myocardial infarction or stroke. Dr. DiBattiste also discussed the next steps in the commercialization of the Prolocor pFCG^TM test.

Click on the following link to see the interview.